Crystal polymorphism in chemical process development

Annual Review of Chemical and Biomolecular Engineering

Volumn 2, Issue , 2011, Pages 259-280

  Lee, Alfred Y ^a   Erdemir, Deniz ^b   Myerson, Allan S ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

crystal growth; crystallization process development; nucleation; phase transformation; polymorph screening; structure property relationship

Indexed keywords

CHEMICAL DEVELOPMENT; CHEMICAL PROCESS DEVELOPMENT; CRYSTAL POLYMORPHISM; CRYSTALLIZATION PROCESS DEVELOPMENT; DRUG SUBSTANCES; PHASE TRANSFORMATION; POLYMORPH SCREENING; QUALITY ATTRIBUTES; SELECTION PROCESS; SOLID FORMS; SOLID-PHASE; STRUCTURE PROPERTY RELATIONSHIPS;

CRYSTAL GROWTH; CRYSTALLIZATION; MOLECULAR CRYSTALS;

DRUG PRODUCTS;

DRUG;

CHEMICAL STRUCTURE; CHEMISTRY; CRYSTALLIZATION; DRUG DESIGN; METHODOLOGY; PHARMACEUTICS; REVIEW;

CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DRUG DESIGN; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY, PHARMACEUTICAL;

EID: 79959385956     PISSN: 19475438     EISSN: None     Source Type: Journal    
DOI: 10.1146/annurev-chembioeng-061010-114224     Document Type: Review

References (132)

1. Bernstein J. 2002. Polymorphism in Molecular Crystals. New York: Oxford Univ. Press. 424 pp.
2. Klaproth MH. 1798. Bergmannische J. I:294-99
3. Mitscherlich E. 1822. On the relationship between crystalline form and chemical composition. I. Note on arsenates and phosphates. Ann. Chim. Phys. 19:350-419
4. Yu L, Reutzel-Edens SM, Mitchell CA. 2000. Crystallization and polymorphism of conformationally flexible molecules: Problems, patterns, and strategies. Org. Process Res. Dev. 4:396-402
5. Roy S,Aitipamula S,NangiaA. 2005. Thermochemical analysis of venlafaxine hydrochloride polymorphs 1-5. Cryst. Growth Des. 5:2268-76 (Pubitemid 41619321)
6. Reutzel-Edens SM, Bush JK, Magee PA, Stephenson GA, Byrn SR. 2003. Anhydrates and hydrates of olanzapine: Crystallization, solid-state characterization, and structural relationships. Cryst. Growth Des. 3:897-907 (Pubitemid 37467740)
7. Hilfiker R, ed. 2006. Polymorphism in the Pharmaceutical Industry.Weinheim:Wiley-VCH. 433 pp.
8. Bhatt PM, Desiraju GR. 2007. Tautomeric polymorphism in omeprazole. Chem. Commun. 2007:2057-59 (Pubitemid 46959487)
9. Byrn SR, Pfeiffer RR, Stowell JG. 1999. Solid State Chemistry of Drugs. West Lafayette, IN: SSCI. 575 pp. 2nd ed.
10. Garcia MA, Lopez C, Claramunt RM, Kenz A, PierrotM, et al. 2002. Polymorphism versus desmotropy: The cases of 3-phenyl- and 5-phenyl-1H-pyrazoles and 3-phenyl-1H-indazole. Helv. Chim. Acta 85:2763-76 (Pubitemid 35177799)
11. BauerM,Harris RK, Rao RC, Apperley DC, Rodger CA. 1998.NMRstudy of desmotropy in irbesartan, a tetrazole-containing pharmaceutical compound. J. Chem. Soc. Perkin Trans. 2 1998:475-81 (Pubitemid 128437971)
12. McCroneWC. 1965. Polymorphism. In Physics and Chemistry of the Organic Solid State, ed. D Fox, MM Labes, AWeissberger, 2:725-67. New York: Wiley Intersci.
13. Brittain HG. 2004. Polymorphism and solvatomorphism. In Profiles of Drug Substances, Excipients, and Related Methodology, ed. HG Brittain, 32:263-83. Amsterdam: Elsevier Acad.
14. Seddon KR. 2004. Pseudopolymorph: A polemic. Cryst. Growth Des. 4:1087 (Pubitemid 39531983)
15. Desiraju GR. 2004. Counterpoint: What's in a name? Cryst. Growth Des. 4:1089-90 (Pubitemid 39531984)
16. Bernstein J. 2005. ⋯ And another comment on pseudopolymorphism. Cryst. Growth Des. 5:1661-62
17. Nangia A. 2006. Pseudopolymorph: Retain this widely accepted term. Cryst. Growth Des. 6:2-4 (Pubitemid 43130513)
18. Morris KR, Rodriguez-Hornedo N. 1993. Hydrates. In Encyclopedia of Pharmaceutical Technology, ed. J Swarbrick, JC Boylan, 7:393-440. New York: Marcel Dekker
19. Griesser UJ. 2006. The importance of solvates. In Polymorphism in the Pharmaceutical Industry, ed. R Hilfiker, pp. 211-33. Weinheim:Wiley-VCH
20. Byrn SR, Xu W, Newman AW. 2001. Chemical reactivity in solid-state pharmaceuticals: Formulation implications. Adv. Drug Deliv. Rev. 48:115-36 (Pubitemid 32452294)
21. Pienaar EW, CairaMR, Lotter AP. 1993. Polymorphs of nitrofurantoin. I. Preparation and X-ray crystal structures of two monohydrated forms of nitrofurantoin. J. Crystallogr. Spectrosc. 23:739-44
22. Vogt FG, Dell'orco PC, Diederich AM, Su Q,Wood JL, et al. 2006. A study of variable hydration states in topotecan hydrochloride. J. Pharm. Biomed. Anal. 40:1080-88 (Pubitemid 43247444)
23. Mirmehrabi M, Rohani S, Murthy KSK, Radatus B. 2004. Improving the filterability and solid density of ranitidine hydrochloride form 1. J. Pharm. Sci. 93:1692-700 (Pubitemid 38823698)
24. Black SN, Cuthbert MW, Roberts RJ, Stensland B. 2004. Increased chemical purity using a hydrate. Cryst. Growth Des. 4:539-44 (Pubitemid 38703346)
25. Wirth DD, Stephenson GA. 1997. Purification of dirithromycin. Impurity reduction and polymorph manipulation. Org. Process Res. Dev. 1:55-60
26. Tanoury GJ, Hett R, Kessler DW,Wald SA, Senanayake CH. 2002. Taking advantage of polymorphism to effect an impurity removal: Development of a thermodynamic crystal form of (R,R)-formoterol tartrate. Org. Process Res. Dev. 6:855-62
27. Brittain HG. 2009. Polymorphism in Pharmaceutical Solids. London/New York: Informa Healthcare. 656 pp. 2nd ed.
28. Brittain HG. 2007. Polymorphism and solvatomorphism 2005. J. Pharm. Sci. 96:705-28 (Pubitemid 46657863)
29. Brittain HG. 2008. Polymorphism and solvatomorphism 2006. J. Pharm. Sci. 97:3611-36
30. Brittain HG. 2009. Polymorphism and solvatomorphism 2007. J. Pharm. Sci. 98:1617-42
31. Brittain HG. 2010. Polymorphism and solvatomorphism 2008. J. Pharm. Sci. 99:3648-64
32. Suryanarayanan R, Byrn SR, eds. 2001. Adv. Drug Deliv. Rev. 48(1). 136 pp.
33. Raw AS, Yu LX, eds. 2004. Adv. Drug Deliv. Rev. 56(3). 184 pp.
34. Rogers RD, ed. 2003. Cryst. Growth Des. 3(6). 176 pp.
35. Rogers RD, ed. 2004. Cryst. Growth Des. 4(6). 360 pp.
36. Rogers RD, ed. 2008. Cryst. Growth Des. 8(1). 362 pp.
37. Majoral JP, Atwood J, eds. 2008. New J. Chem. 32(10). 164 pp.
38. Laird T, ed. 2000. Org. Process Res. Dev. 4(5). 66 pp.
39. Laird T, ed. 2003. Org. Process Res. Dev. 7(6). 70 pp.
40. Laird T, ed. 2005. Org. Process Res. Dev. 9(6). 93 pp.
41. Laird T, ed. 2009. Org. Process Res. Dev. 13(6). 173 pp.
42. Buerger MJ, Bloom MC. 1937. Crystal polymorphism. Z. Kristallogr. 96:182-200
43. Kuhnert-Brandstatter M. 1975. Polymorphie bei Arzneistoffen. Pharm. Unserer Zeit 4:131-37
44. Stahly GP. 2007. Diversity in single- and multiple-component crystals. The search for and prevalence of polymorphs and cocrystals. Cryst. Growth Des. 7:1007-26
45. Grunenberg A. 1997. Polymorphie und thermische analyse pharmazeutischer wirkstoffe. Pharmazie 26:224-31 (Pubitemid 27514542)
46. Infantes L, Fabian L, Motherwell WDS. 2007. Organic crystal hydrates: What are the important factors for formation. CrystEngComm 9:65-71
47. Haynes DA, JonesW, Motherwell WDS. 2005. Occurrence of pharmaceutically acceptable anions and cations in the Cambridge Structural Database. J. Pharm. Sci. 94:2111-20 (Pubitemid 41665273)
48. Nangia A, Desiraju GR. 1999. Pseudopolymorphism: Occurrences of hydrogen bonding organic solvents in molecular crystals. Chem. Commun. 1999:605-6 (Pubitemid 29158703)
49. Bingham AL, Hughes DS, Hursthouse MB, Lancaster RW, Tavener S, et al. 2001. Over one hundred solvates of sulfathiazole. Chem. Commun. 2001:603-4 (Pubitemid 32291294)
50. Yu L. 2010. Polymorphism in molecular solids: An extraordinary system of red, orange, and yellow crystals. Acc. Chem. Res. 43:1257-66
51. Yu L. 2002. Color changes by conformational polymorphism: Optical-crystallography, single-crystal spectroscopy, and computational chemistry. J. Phys. Chem. A 106:544-50 (Pubitemid 35264052)
52. Pudipeddi M, Serajuddin ATM. 2005. Trends in solubility of polymorphs. J. Pharm. Sci. 94:929-39 (Pubitemid 40780760)
53. Chemburkar SR, Bauer J,Deming K, SpiwekH, Patel K, et al. 2000. Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development. Org. Process Res. Dev. 4:413-17
54. DeVilliersMM,van der Watt JG, LotterAP. 1992. Kinetic study of the solid-state photolytic degradation of two polymorphic forms of furosemide. Int. J. Pharm. 88:275-83 (Pubitemid 23000430)
55. Griesser UJ, Jetti RKR, Haddow MF, Brehmer T, Apperley DC, et al. 2008. Conformational polymorphism in oxybuprocaine hydrochloride. Cryst. Growth Des. 8:44-56
56. Agbada CO, York P. 1994. Dehydration of theophylline monohydrate powder: Effects of particle size and sample weight. Int. J. Pharm. 106:33-40 (Pubitemid 24110062)
57. Velaga SP, Vangala VR,Basavoju S,Bostrom D. 2010. Polymorphism in acesulfame sweetener: Structureproperty and stability relationships of bending and brittle crystals. Chem. Commun. 2010:3562-64
58. Yu LX, Furness MS, Raw A, Woodland Outlaw KP, Nashed NE, et al. 2003. Scientific considerations of pharmaceutical solid polymorphism in abbreviated new drug applications. Pharm. Res. 20:531-36 (Pubitemid 36438894)
59. Cabri W,Ghett P, Giovanni P, AlpegianiM. 2007. Polymorphisms and patent, market, and legal battles: Cefdinir case study. Org. Process Res. Dev. 11:64-72
60. Cogen JM, Hilmer AJ. 2008. Crystal polymorphism in antioxidant-metal deactivator 1,2-bis(3,5-di-tertbutyl- 4-hydroxyhydrocinnamoyl)hydrazine. Polym. Degrad. Stab. 93:2193-98
61. Saunier J, Mazel V, Paris C, Yagoubi N. 2010. Polymorphism of Irganox 1076: Discovery of new forms and direct characterization of the polymorphs on a medical device by Raman microspectroscopy. Eur. J. Pharm. Biopharm. 75:443-50
62. Wada Y, Matsubara T. 1992. Pseudo-polymorphism and crystalline transition of magnesium stearate. Thermochim. Acta 196:63-84
63. TrainiD, Young PM, Thielmann F, Acharya M. 2008. The influence of lactose pseudopolymorphic form on salbutamol sulfate-lactose interactions in DPI formulations. Drug Dev. Ind. Pharm. 34:992-1001
64. Palucki M, Higgins JD, Kwong E, Templeton AC. 2010. Strategies at the interface of drug discovery and development: Early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates. J. Med. Chem. 53:5897-905
65. Bauer J, Spanton S, Henry R, Quick J, Dziki W, et al. 2001. Ritonavir: An extraordinary example of conformational polymorphism. Pharm. Res. 18:859-66 (Pubitemid 32783524)
66. Pesti JA, Chorvat RJ, Huhn GF. 2000. A better drug for Alzheimer'š Chem. Innov. 30:28-37
67. Dunn PJ, Hughes ML, Searle PM, Wood AS. 2003. The chemical development and scale-up of sampatrilat. Org. Process Res. Dev. 7:244-53 (Pubitemid 36706784)
68. Prashad M, Sutton P, Wu R, Hu B, Vivelo J, et al. 2010. Process research and development of a MTP inhibitor: Another case of disappearing polymorph upon scale-up. Org. Process. Res. Dev. 14:878-82
69. Anderton C. 2004. A valuable technique for polymorph screening. Eur. Pharm. Rev. 9:68-74
70. Morissette SL, Almarsson O, Peterson ML, Remenar JF, Read MJ, et al. 2004. High-throughput crystallization: Polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv. Drug Delivery Rev. 56:275-300 (Pubitemid 38201426)
71. Maiwald M. 2006. Examining the range of methods available to derive numerous polymorphic forms. Am. Pharm. Rev. 9:95-99
72. Miller J, Rodriguez-Hornedo N, Blackburn A, Macikenas D, Collman B. 2007. Solvent systems for crystallization and polymorph selection. In Solvent Systems and Their Selection in Pharmaceutics and Biopharmaceutics, ed. P Augustijns, ME Brewster, pp. 53-109. New York: AAPS
73. Zhang GGZ, Zhou D. 2009. Crystalline and amorphous solids. In Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice, ed. Y Qiu, Y Chen, GGZ Zhang, pp. 87-146. New York: Academic
74. Alleso M, Tian F, Cornett C, Rantanen J. 2010. Towards effective solid form screening. J. Pharm. Sci. 99:3711-18
75. Miller JM, Collman BM,GreeneLR, GrantDJW,BlackburnAC. 2005. Identifying the stable polymorph early in the drug discovery-development process. Pharm. Dev. Technol. 10:291-97 (Pubitemid 40677449)
76. Cui Y, Yao E. 2008. Evaluation of hydrate screening methods. J. Pharm. Sci. 97:2730-44
77. Getsoian A, Lodaya RM, Blackburn AC. 2008. One-solvent polymorph screen of carbamazepine. Int. J. Pharm. 348:3-9 (Pubitemid 350266231)
78. Carlton RA. 2006. Experimental methods in the study of thermodynamic polymorph stability relationships. Am. Pharm. Rev. 9:88-93
79. Ticehurst MD, StoreyRA, Watt C. 2002. Application of slurry bridging experiments at controlled water activities to predict the solid-state conversion between anhydrous and hydrated forms using theophylline as a model compound. Int. J. Pharm. 247:1-10 (Pubitemid 35341134)
80. Llinas A, Goodman JM. 2008. Polymorph control: Past, present and future. Drug Discov. Today 13:198-210
81. SinghalD, Curatolo W. 2004. Drug polymorphism and dosage form design: A practical perspective. Adv. Drug Deliv. Rev. 56:335-47 (Pubitemid 38201429)
82. Myrdal PB, Jozwiakowski MJ. 2008. Alteration of the solid state of the drug substances: Polymorphs, solvates, and amorphous forms. In Water-Insoluble Drug Formulation, ed. R Liu, pp. 531-66. Boca Raton, FL: CRC Press. 2nd ed.
83. Cote A, Zhou G, Stanik M. 2009. A novel crystallization methodology to ensure isolation of the most stable crystal form. Org. Process Res. Dev. 13:1276-83
84. Parsons AR, Black SN,CollingR. 2003. Automatedmeasurement of metastable zones for pharmaceutical compounds. Chem. Eng. Res. Dev. 81:700-4 (Pubitemid 37002472)
85. Muller FL, Fielding M, Black S. 2009. A practical approach for using solubility to design cooling crystallizations. Org. Process Res. Dev. 13:1315-21
86. Beckmann W. 2000. Seeding the desired polymorph: Background, possibilities, limitations, and case studies. Org. Process Res. Dev. 4:372-83
87. Cimarosti Z, Castagnoli C, Rossetti M, Scarati M, Day C, et al. 2010. Development of drug substances as mixture of polymorphs: Studies to control Form 3 in casopitant mesylate. Org. Process. Res. Dev. 14:1337-46
88. Beckmann W, Nickisch K, Budde U. 1998. Development of a seeding technique for the crystallization of the metastable A modification of abecarnil. Org. Process Res. Dev. 2:298-304
89. MüllerM,Meier U, Wieckhusen D, Beck R, Pfeffer-Hennig S, et al. 2005. Process development strategy to ascertain reproducible API polymorph manufacture. Cryst. Growth Des. 6:946-54 (Pubitemid 43672332)
90. Yu L. 2003. Nucleation of one polymorph by another. J. Am. Chem. Soc. 125:6380-81 (Pubitemid 36605402)
91. Chen S, Xi H, Yu L. 2005. Cross-nucleation between ROY polymorphs. J. Am. Chem. Soc. 127:17439-44 (Pubitemid 41791064)
92. Black SN, Phillips A, Scott CI. 2009. Crystallization design space: Avoiding a hydrate in a water-based process. Org. Process Res. Dev. 13:78-83
93. Bernstein J, Davey RJ, Henck JO. 1999. Concomitant polymorphs. Angew. Chem. Int. Ed. 38:3440-61
94. Cardew PT, Davey RJ. 1985. The kinetics of solvent-mediated phase transformation. Proc. R. Soc. Lond. A 398:415-28
95. Wei C, Yang BS. 2006. U.S. Publication No. 2006/0160841
96. Davey RJ, Blagden N, Potts GD, Docherty R. 1997. Polymorphism in molecular crystals: Stabilization of a metastable form by conformational mimicry. J. Am. Chem. Soc. 119:1767-72 (Pubitemid 27145524)
97. Cashell C, SuttonD,CorcoranD,Hodnett BK. 2003. Inclusion of the stable form of a polymorph within crystals of its metastable form. Cryst. Growth Des. 3:869-72 (Pubitemid 37467737)
98. Mohan R, Koo KK, Strege C, Myerson AS. 2001. Effect of additives on the transformation behavior of L-phenylalanine in aqueous solution. Ind. Eng. Chem. Res. 40:6111-17 (Pubitemid 34015081)
99. Kline BJ, Saenz J, Stankovic N, Mitchell MB. 2006. Polymorph and particle size control of PPAR compounds PF00287586 and AG035029. Org. Process Res. Dev. 10:203-11 (Pubitemid 43508431)
100. Mangin D, Puel F, Veesler S. 2009. Polymorphism in processes of crystallization in solution: A practical review. Org. Process Res. Dev. 13:1241-53
101. Croker D, Hodnett BK. 2010. Mechanistic features of polymorphic transformations: The role of surfaces. Cryst. Growth Des. 10:2806-16
102. Campeta AM, Chekal BP, Abramov YA, Meenan PA, Henson MJ, et al. 2010. Development of a targeted polymorph screening approach for a complex polymorphic and highly solvating API. J. Pharm. Sci. 99:3874-86
103. Samas B, Seadeek C, Campeta AM, Chekal BP. 2011. A thermodynamic-based approach to analyzing a highly solvating polymorphic system: The desolvation window method. J. Pharm. Sci. 100:186-94
104. Cypes SH, Wenslow RM, Thomas SM, Chen AM, Dorwart JG, et al. 2004. Drying an organic monohydrate: Crystal form instabilities and a factory-scale drying scheme to ensure monohydrate preservation. Org. Process Res. Dev. 8:576-82 (Pubitemid 39107496)
105. Stephenson GA, Groleau EG, Kleemann RL, Xu W, Rigsbee DR. 1998. Formation of isomorphic desolvates: Creating a molecular vacuum. J. Pharm. Sci. 87:536-42 (Pubitemid 28225615)
106. Shiraki M. 2010. Physical characterization of TRK-720 hydrate, the very late antigen-4 (VLA-4) inhibitor, as a solid form for inhalation: Preparation of the hydrate by solvent exchange among its solvates and mechanistical considerations. J. Pharm. Sci. 99:3986-4004
107. Brittain HG. 2002. Effects of mechanical processing on phase composition. J. Pharm. Sci. 91:1573-80 (Pubitemid 34680220)
108. Sonje VM, Kumar L, Meena CL, Kohli G, Puri G, et al. 2010. Atorvastatin calcium. In Profiles of Drug Substances, Excipients, and Related Methodology, ed. HG Brittain, 35:1-70. Amsterdam: Elsevier Acad.
109. Uvarov V, Popov I. 2008. Development and metrological characterization of quantitative X-ray diffraction phase analysis for the mixtures of clopidogrel bisulfate polymorphs. J. Pharm. Bio. Anal. 46:676-82
110. Lestari MLAD, Suciati, Indrayanto G, Brittain HG. 2010. Clopidogrel bisulfate. In Profiles of Drug Substances, Excipients, and Related Methodology, ed. HG Brittain, 35:71-115. Amsterdam: Elsevier Acad.
111. Murnane D, Marriott C, Martin GP. 2008. Crystallization and crystallinity of fluticasone propionate. Cryst. Growth Des. 8:2753-64
112. Murnane D, Marriott C, Martin GP. 2008. Polymorphic control of inhalation microparticles prepared by crystallization. Int. J. Pharm. 361:141-49
113. Rukhman I, Flyaks E, Koltai T, Aronhime J. 2006. U.S. Patent No. 7,105,557
114. BraunDE, Gelbrich T, Kahlenberg V, Tessadri R,Wieser J, et al. 2009. Stability of solvates and packing systematics of nine crystal forms of the antipsychotic drug aripiprazole. Cryst. Growth Des. 9:1054-65
115. Casar R. 2010. U.S. Publication No. 2010/0016370
116. Parthasaradhi RB, Rathnakar RK, Raji RR, Muralidhara RD, Chander RKS. 2007. U.S. Patent No. 7,238,686
117. Blatter F, Van Der Schaaf PA, Szelagiewicz M. 2008. U.S. Publication No. 2008/0194604
118. Chou JH, Gentzler MB, Michaels, JN, Bazin C, Clas SD, et al. 2009. U.S. Patent No. 7,560,559
119. Maggon K. 2010. Top ten/twenty best selling drugs 2009. http://knol.google.com/k/top-ten-twenty-bestselling-drugs-2009
120. Peterson ML, McIlroy D, Shaw P, Mustonen JP, Oliveiera M, et al. 2003. Crystallization and transformation of acetaminophen trihydrate. Cryst. Growth Des. 3:761-65 (Pubitemid 37162287)
121. Fabbiani FPA, Allan DR,Dawson A,David WIF, McGregor PA, et al. 2003. Pressure-induced formation of a solvate of paracetamol. Chem. Commun. 2003:3004-5 (Pubitemid 38019245)
122. Bond AD, Boese R, Desiraju GR. 2007. On the polymorphism of aspirin: Crystalline aspirin as intergrowths of two "polymorphic" domains. Angew. Chem. Int. Ed. 46:618-22 (Pubitemid 46159212)
123. Hegedus B, Gorog S. 1985. The polymorphism of cimetidine. J. Pharm. Biomed. Anal. 3:303-13 (Pubitemid 15237058)
124. Al-Omar MA, Al-Mohizea AM. 2009. Famotidine. In Profiles of Drug Substances, Excipients, and Related Methodology, ed. HG Brittain, 34:115-51. Amsterdam: Elsevier Acad.
125. Higgins JD, Gilmor TP, Martellucci SA, Bruce RD, Brittain HG. 2001. Ibuprofen. In Analytical Profiles of Drug Substances and Excipients, ed. HG Brittain, 27:265-300. San Diego: Academic (Pubitemid 33805290)
126. Dudognon E, Danede F, Descamps M, Correia NT. 2008. Evidence for a new crystalline phase of racemic ibuprofen. Pharm. Res. 25:2853-58
127. Newman AW, Andres MC, Stahly GP, Ohannessian L, Adair A. 2002. Unsolvated enantiotropic polymorphs of loperamide hydrochloride. AAPS PharmSci 4(S1):1816 (Abstr.)
128. CairaMR, Gerber JJ, Lotter AP. 1995. Hydration of drug molecules: Cavity inclusion of water in crystals of loperamide hydrochloride tetrahydrate. Supramol. Chem. 5:225-30
129. Gala D, Dibenedetto DJ. 2002. U.S. Patent No. 6,335,347
130. Kim YS, Rousseau RW. 2004. Characterization and solid-state transformations of the pseudopolymorphic forms of sodium naproxen. Cryst. Growth Des. 4:1211-16 (Pubitemid 39532000)
131. Chavez KJ, Guevara M, Rousseau RW. 2010. Characterization of solvates formed by sodium naproxen and an homologous series of alcohols. Cryst. Growth Des. 10:3372-77
132. Trifkovic M, Rohani S. 2007. Polymorphic generation through solvent selection: Ranitidine hydrochloride. Org. Process Res. Dev. 11:138-43